Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding during its initial public offering in September 2024 [2][3]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected net proceeds from the IPO [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period and were negligently prepared [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO